Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy

Publication date: Available online 31 October 2017Source: Seminars in Cancer BiologyAuthor(s): Sergey G. Klochkov, Margarita E. Neganova, Nagendra Sastry Yarla, Madhukiran Parvathaneni, Bechan Sharma, Vadim V. Tarasov, George Barreto, Sergey O. Bachurin, Ghulam Md Ashraf, Gjumrakch AlievAbstractRas proteins have been reported to play key role in oncologic diseases. Ras proteins are associated with cellular membranes for its carcinogenic activities through post-translational modifications, including farnesylation. Farnesyltransferase is responsible for a type of Ras membrane targeting, which leads to cancer origin and progression. Inhibitors of farnesyltransferase have been developed as novel anticancer agents. In this review, the role of farnesyltransferase in cancer progression and development has been discussed. Further, the current status of development of farnesyltransferase inhibitors for cancer prevention and treatment has also been reviewed.
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research